EVOKE PHARMA INC's ticker is EVOK and the CUSIP is 30049G104. A total of 27 filers reported holding EVOKE PHARMA INC in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $82,000 | +18.8% | 27,500 | 0.0% | 0.00% | – |
| Q2 2018 | $69,000 | +21.1% | 27,500 | 0.0% | 0.00% | – |
| Q1 2018 | $57,000 | +103.6% | 27,500 | +120.0% | 0.00% | – |
| Q4 2017 | $28,000 | -53.3% | 12,500 | -30.6% | 0.00% | – |
| Q3 2017 | $60,000 | +30.4% | 18,000 | 0.0% | 0.00% | – |
| Q2 2017 | $46,000 | -17.9% | 18,000 | 0.0% | 0.00% | – |
| Q1 2017 | $56,000 | – | 18,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 242,500 | $1,962,000 | 1.69% |
| SOPHROSYNE CAPITAL LLC | 49,000 | $397,000 | 0.40% |
| LMR Partners LLP | 23,882 | $187,000 | 0.02% |
| GEODE CAPITAL MANAGEMENT, LLC | 10,276 | $80,000 | 0.00% |
| BlackRock Investment Management, LLC | 489 | $4,000 | 0.00% |
| MORGAN STANLEY | 500 | $4,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 84 | $1,000 | 0.00% |
| VANGUARD GROUP INC | 48,394 | $378,000 | 0.00% |
| UBS AG | 727 | $6,000 | 0.00% |
| BANK OF AMERICA CORP /DE/ | 33,500 | $271,000 | 0.00% |